Notifications

Home

Stocks
- Stock Screener
- Market Movers
- Insider Trades
- Upcoming Earnings
- Upcoming Dividends
Options
- Unusual Options Activity
- Implied Volatility Rank
- Volatility %Change
News
Upcoming IPOs

Plus Therapeutics Inc (PSTV)

$3.96 -0.12 (-2.94%)

Overview
Financial
Short Interest
Institutional Holdings
Dividends
Charts

Market Cap	28.09M
Revenue (ttm)	5.21M
Net Income (ttm)	-22.39M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-429.75%
Debt to Equity Ratio	0.06

Volume	96,300
Avg Vol	197,148
Day's Range	N/A - N/A
Shares Out	6.88M
Stochastic %K	4%
Beta	1.38
Analysts	Sell
Price Target	$34.50

Company Profile

Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. The company's lead radiotherapeutic candidate is rhenium obisbemeda, a patented radiotherapy for patients with central nervous system and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere to treat va...

Industry: Biotechnology

Sector: Healthcare

Phone: 737 255 7194

Fax: 210 974 6901

Website: plustherapeutics.com

Address:

6420 LEVIT GREEN BOULEVARD, SUITE 210, Houston, United States

TheVirus0011 Jun. 25 at 1:04 AM

$PSTV I have a feeling it's going to rise within the next 15 days.

0 · Reply

Investor1862 Jun. 24 at 10:18 PM

$PSTV below 1 by end of year, another reverse split to follow. Con artists.

0 · Reply

flywithfitz81 Jun. 24 at 7:59 PM

$PSTV

0 · Reply

Jc237 Jun. 24 at 3:17 PM

$PSTV they have announced several great updates over the past year putting a foundation down, I will jump back in when They actually start selling cnside or positive test results.

0 · Reply

Longintactandinminent Jun. 24 at 2:59 PM

$PSTV 2.92 looking possible

0 · Reply

Longintactandinminent Jun. 24 at 2:47 PM

$PSTV granny went all in

0 · Reply

Longintactandinminent Jun. 24 at 2:02 PM

$PSTV

0 · Reply

Longintactandinminent Jun. 24 at 1:00 PM

$PSTV

0 · Reply

Igotgame1 Jun. 24 at 12:46 PM

$PSTV turnaround

0 · Reply

Longintactandinminent Jun. 24 at 3:15 AM

$PSTV

0 · Reply

Plus Therapeutics to Provide Business Update Call on June 30, 2026

Jun 5, 2026, 8:00 AM EDT - 19 days ago

Plus Therapeutics Registration statement: Registration filing

Jun 4, 2026, 7:30 AM EDT - 20 days ago

Plus Therapeutics Announces CAP Accreditation of CNSide® Diagnostics Clinical Laboratory

Jun 2, 2026, 8:00 AM EDT - 22 days ago

Plus Therapeutics Registration statement: Registration filing

2026-06-02T10:13:30.000Z - 22 days ago

Plus Therapeutics files $100M mixed securities shelf

2026-05-26T13:10:52.000Z - 4 weeks ago

Plus announces presentation of health economics study on CNSide CSF assay

May 26, 2026, 7:30 AM EDT - 4 weeks ago

Plus' CNSide Diagnostic Platform Demonstrates Substantial Healthcare Cost Reduction in Patients with Leptomeningeal Metastases

2026-05-19T11:35:32.000Z - 5 weeks ago

Plus Therapeutics enters pact with Ephemeral for AI execution platform

May 19, 2026, 7:30 AM EDT - 5 weeks ago

Plus Therapeutics Partners with Ephemeral Technologies to Deploy AI Execution Platform for CNS Oncology

2026-05-15T20:11:34.000Z - 5 weeks ago

Plus Therapeutics reports Q1 EPS ($1.05), consensus (87c)

May 15, 2026, 4:05 PM EDT - 5 weeks ago

Plus Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update on REYOBIQ™ Clinical Program and CNSide® Commercial Rollout

May 15, 2026, 4:00 PM EDT - 5 weeks ago

Plus Therapeutics Earnings release: Q1 2026

May 15, 2026, 4:00 PM EDT - 5 weeks ago

Plus Therapeutics Quarterly report: Q1 2026

May 14, 2026, 9:00 AM EDT - 5 weeks ago

Plus Therapeutics Transcript: AGM 2026

May 8, 2026, 7:30 AM EDT - 6 weeks ago

Plus Therapeutics Announces Oral Presentation Highlighting REYOBIQ™ Clinical and Translational Data Demonstrating Favorable Safety, Survival, and Emerging Immunomodulation in Leptomeningeal Metastases

May 8, 2026, 7:00 AM EDT - 6 weeks ago

Plus Therapeutics Slides: FY 2026

May 7, 2026, 7:30 AM EDT - 6 weeks ago

Plus Therapeutics Receives Medicare Enrollment Approval for CNSide Diagnostic

Apr 28, 2026, 7:30 AM EDT - 2 months ago

Plus Therapeutics Secures Blue Shield of California Coverage for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer

Apr 23, 2026, 7:30 AM EDT - 2 months ago

Plus Therapeutics Initiates Manufacturing Activities with SpectronRx Under a Master Services Agreement to Support GMP Pivotal Trial Readiness for REYOBIQ™

Apr 22, 2026, 4:30 PM EDT - 2 months ago

Plus Therapeutics Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

2026-04-21T11:59:57.000Z - 2 months ago

Plus Therapeutics regains compliance with Nasdaq minimum bid price requirement

Apr 21, 2026, 7:30 AM EDT - 2 months ago

Plus Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

Apr 15, 2026, 7:30 AM EDT - 2 months ago

Plus Therapeutics Appoints Randy H. Goodman, PhD, MHA, as Vice President of Value Strategy & HEOR to Advance Market Access and Commercial Execution

2026-04-09T11:57:58.000Z - 2 months ago

Plus Therapeutics appoints Eric Daniels as chief development officer

Apr 9, 2026, 7:30 AM EDT - 2 months ago

Plus Therapeutics Appoints Eric J. Daniels, M.D.

2026-04-08T11:39:50.000Z - 2 months ago

Plus Therapeutics granted Orphan Drug Designation for Reyobiq

Apr 8, 2026, 7:30 AM EDT - 2 months ago

Plus Therapeutics Granted U.S. FDA Orphan Drug Designation to REYOBIQ™ in Pediatric Malignant Gliomas

2026-04-07T15:15:27.000Z - 2 months ago

Plus Therapeutics price target lowered to $12 from $37.50 at Maxim

2026-04-07T11:55:34.000Z - 2 months ago

Plus CNSide Cerebrospinal Fluid Tumor Cell Enumeration test gets AMA PLA code

Apr 7, 2026, 7:30 AM EDT - 2 months ago

Plus Therapeutics Receives AMA PLA Code for CNSide® CSF Tumor Cell Enumeration Test, Advancing Reimbursement and U.S. Commercial Adoption

2026-04-06T22:20:10.000Z - 2 months ago

Plus Therapeutics’ treatment of malignant glioma granted FDA orphan designation

Apr 2, 2026, 7:30 AM EDT - 2 months ago

Plus Therapeutics Secures Highmark Coverage for CNSide® CSF Assay, Expanding Reimbursement to ~75 Million Covered Lives

2026-04-01T23:50:16.000Z - 3 months ago

Plus Therapeutics Inc (USA) trading halted, news pending

2026-03-31T14:45:55.000Z - 3 months ago

Plus Therapeutics downgraded to Hold from Buy at D. Boral Capital

Mar 31, 2026, 8:00 AM EDT - 3 months ago

Plus Therapeutics Proxy statement: Proxy filing

Mar 31, 2026, 8:00 AM EDT - 3 months ago

Plus Therapeutics Proxy statement: Proxy filing

2026-03-31T11:38:10.000Z - 3 months ago

Plus Therapeutics announces 1-for-25 reverse stock split

Mar 26, 2026, 7:30 AM EDT - 3 months ago

Plus Therapeutics Appoints Diagnostics and Molecular Diagnostics Industry Leader Ron Andrews to its Board of Directors

2026-03-19T12:01:47.000Z - 3 months ago

Plus Therapeutics’ CNSide assay may reduce healthcare costs

Mar 19, 2026, 7:30 AM EDT - 3 months ago

Plus Therapeutics to Present New Analysis at ISPOR Showing CNSide® May Reduce Leptomeningeal Metastases Healthcare Costs by 40%

2026-03-12T21:05:16.000Z - 3 months ago

Plus Therapeutics reports Q4 EPS (29c), consensus (4c)

Mar 12, 2026, 4:15 PM EDT - 3 months ago

Plus Therapeutics Reports 2025 Results, Business Progress and 2026 Anticipated Milestones for REYOBIQ™ Clinical Program and CNSide® Commercial Rollout

Mar 12, 2026, 7:00 AM EDT - 3 months ago

Plus Therapeutics Earnings release: Q4 2025

Mar 12, 2026, 7:00 AM EDT - 3 months ago

Plus Therapeutics Annual report: Q4 2025

2026-02-25T12:39:49.000Z - 4 months ago

Plus announces new Category III CPT code for CED used with Reyobiq

Feb 25, 2026, 7:30 AM EST - 4 months ago

Plus Therapeutics Announces New Category III CPT Code for Convection-Enhanced Delivery Used with REYOBIQ™

2026-02-03T13:40:32.000Z - 5 months ago

Plus Therapeutics initiated with a Buy at Lake Street

2026-01-23T15:00:32.000Z - 5 months ago

Plus Therapeutics price target lowered to $1.50 from $3 at Maxim

2026-01-23T11:11:22.000Z - 5 months ago

Plus Therapeutics price target lowered to $1 from $2 at H.C. Wainwright

Jan 22, 2026, 9:00 AM EST - 5 months ago

Plus Therapeutics Transcript: Business update

Jan 22, 2026, 9:00 AM EST - 5 months ago

Plus Therapeutics Press release: Business update

Jan 22, 2026, 9:00 AM EST - 5 months ago

Plus Therapeutics Slides: Business update

2026-01-22T12:50:20.000Z - 5 months ago

Plus Therapeutics announces anticipated milestones for FY26

Jan 21, 2026, 4:15 PM EST - 5 months ago

Plus Therapeutics to Provide Business Update and Host Conference Call on Thursday, January 22, 2026 at 9:00 A.M. ET

Jan 14, 2026, 8:00 AM EST - 5 months ago

Plus Therapeutics Announces Pricing of Upsized $15 Million Public Offering

Jan 9, 2026, 7:00 AM EST - 5 months ago

Plus Therapeutics Registration statement: Registration Filing

Jan 8, 2026, 7:30 AM EST - 5 months ago

Plus Therapeutics Announces Read Out of Type B Meeting with the FDA with Goal of Accelerating Approval of REYOBIQ™ for Leptomeningeal Metastases

Dec 11, 2025, 7:30 AM EST - 6 months ago

Plus Therapeutics Expands CNSide Assay Platform to State of California

Dec 9, 2025, 7:30 AM EST - 7 months ago

Plus Therapeutics Announces Expansion of CNSide Team and Issuance of Inducement Grants

Dec 4, 2025, 7:30 AM EST - 7 months ago

Plus Therapeutics Highlights Three REYOBIQ™ Clinical Data Presentations at 2025 WFNOS/SNO Annual Meeting

Dec 1, 2025, 7:30 AM EST - 7 months ago

Plus Therapeutics to Present ReSPECT Phase 1 Dose Escalation Study Results for Leptomeningeal Metastases at the 2025 San Antonio Breast Cancer Symposium

Nov 24, 2025, 7:30 AM EST - 7 months ago

Plus Therapeutics Announces Completion of U.S. FDA Meeting on Future Clinical Development Plans for REYOBIQ™ in Leptomeningeal Metastases

Nov 20, 2025, 7:30 AM EST - 7 months ago

Plus Therapeutics Secures National Coverage Agreement with Humana for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer

Nov 17, 2025, 7:30 AM EST - 7 months ago

Plus Therapeutics Granted 180-Day Extension to Regain Compliance with Nasdaq's Minimum Bid Price Requirement

Nov 6, 2025, 7:30 AM EST - 8 months ago

Plus Therapeutics Highlights ReSPECT-LM Clinical Trial Results at 40th SITC Annual Meeting, Melanoma Research Foundation Brain Metastases Summit 4.0

Oct 30, 2025, 5:00 PM EDT - 8 months ago

Plus Therapeutics Quarterly report: Q3 2025

Oct 30, 2025, 5:00 PM EDT - 8 months ago

Plus Therapeutics Earnings release: Q3 2025

Oct 30, 2025, 4:15 PM EDT - 8 months ago

Plus Therapeutics Reports Third Quarter Financial Results and Recent Business Highlights

Oct 21, 2025, 7:30 AM EDT - 8 months ago

Plus Therapeutics Updates on CNSide® Diagnostic Platform Launch

Sep 25, 2025, 7:30 AM EDT - 9 months ago

Plus Therapeutics Announces National Coverage Agreement with UnitedHealthcare Insurance Company for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer

Sep 22, 2025, 7:30 AM EDT - 9 months ago

Plus Therapeutics Announces Additional $1.9 Million Advance Payment from CPRIT

Sep 18, 2025, 7:30 AM EDT - 9 months ago

Plus Therapeutics Announces Successful Accreditation and Certification for Its CNSide® Diagnostics Clinical Laboratory

Sep 2, 2025, 4:15 PM EDT - 10 months ago

Plus Therapeutics to Participate in Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 26, 2025, 7:30 AM EDT - 10 months ago

Plus Therapeutics Regains Compliance with Applicable Nasdaq Listing Criteria

Aug 18, 2025, 7:30 AM EDT - 11 months ago

Plus Therapeutics Presents Positive ReSPECT-LM Clinical Trial Results of REYOBIQ™ in Leptomeningeal Metastases

Aug 15, 2025, 7:30 AM EDT - 11 months ago

Plus Therapeutics Reports Stockholders' Equity in Excess of $2.5 million in Compliance with Nasdaq Equity Requirements

Aug 14, 2025, 4:15 PM EDT - 11 months ago

Plus Therapeutics Reports Second Quarter Financial Results and Recent Business Highlights

Aug 14, 2025, 4:00 PM EDT - 11 months ago

Plus Therapeutics Quarterly report: Q2 2025

Aug 14, 2025, 4:00 PM EDT - 11 months ago

Plus Therapeutics Earnings release: Q2 2025

Aug 14, 2025, 7:30 AM EDT - 11 months ago

Plus Therapeutics Presents Positive CNSide CSF Assay Platform Results at the 2025 SNO/ASCO CNS Metastases Conference

Aug 12, 2025, 8:00 AM EDT - 11 months ago

Plus Therapeutics Registration statement: Registration Filing

Aug 1, 2025, 8:00 AM EDT - 11 months ago

Plus Therapeutics Proxy statement: Proxy Filing

Jul 31, 2025, 7:30 AM EDT - 11 months ago

Plus Therapeutics Provides US Launch Update for its CNSide® Diagnostic

Jul 23, 2025, 7:30 AM EDT - 1 year ago

Plus Therapeutics Announces $1.6 Million Advance Payment from CPRIT

Jul 21, 2025, 8:00 AM EDT - 1 year ago

Plus Therapeutics Proxy statement: Proxy Filing

Jul 15, 2025, 7:30 AM EDT - 1 year ago

Plus Therapeutics Presents ReSPECT-LM Clinical Trial Results for REYOBIQ™ in Patients with Leptomeningeal Metastases

Jul 11, 2025, 8:00 AM EDT - 1 year ago

Plus Therapeutics Proxy statement: Proxy Filing

Jul 10, 2025, 7:30 AM EDT - 1 year ago

Plus Therapeutics Announces Two CNSide Presentations at the Upcoming SNO/ASCO CNS Metastases Conference

Jul 8, 2025, 7:30 AM EDT - 1 year ago

Plus Therapeutics Announces Initial Patients Successfully Treated in ReSPECT-LM Dose Optimization Trial for REYOBIQ™ in Leptomeningeal Metastases

Jun 30, 2025, 7:30 AM EDT - 1 year ago

Plus Therapeutics Announces FDA Agreement to Initiate ReSPECT-LM Dose Optimization Trial for REYOBIQ™ in Leptomeningeal Metastases

Jun 26, 2025, 9:00 AM EDT - 1 year ago

Plus Therapeutics Transcript: Business Update

Jun 26, 2025, 9:00 AM EDT - 1 year ago

Plus Therapeutics Press release: Business Update

Jun 26, 2025, 7:30 AM EDT - 1 year ago

Plus Therapeutics Provides Business Update on CNSide Diagnostics Subsidiary

Jun 25, 2025, 4:15 PM EDT - 1 year ago

Plus Therapeutics to Provide Business Update and Host Conference Call on Thursday, June 26, 2025 at 9:00 A.M. ET

TheVirus0011 Jun. 25 at 1:04 AM

$PSTV I have a feeling it's going to rise within the next 15 days.

0 · Reply

Investor1862 Jun. 24 at 10:18 PM

$PSTV below 1 by end of year, another reverse split to follow. Con artists.

0 · Reply

flywithfitz81 Jun. 24 at 7:59 PM

$PSTV

0 · Reply

Jc237 Jun. 24 at 3:17 PM

$PSTV they have announced several great updates over the past year putting a foundation down, I will jump back in when They actually start selling cnside or positive test results.

0 · Reply

Longintactandinminent Jun. 24 at 2:59 PM

$PSTV 2.92 looking possible

0 · Reply

Longintactandinminent Jun. 24 at 2:47 PM

$PSTV granny went all in

0 · Reply

Longintactandinminent Jun. 24 at 2:02 PM

$PSTV

0 · Reply

Longintactandinminent Jun. 24 at 1:00 PM

$PSTV

0 · Reply

Igotgame1 Jun. 24 at 12:46 PM

$PSTV turnaround

0 · Reply

Longintactandinminent Jun. 24 at 3:15 AM

$PSTV

0 · Reply

Duke2021 Jun. 23 at 5:54 PM

$PSTV This turd will finish red

0 · Reply

Longintactandinminent Jun. 23 at 2:40 PM

$PSTV marky Marc I c u

0 · Reply

Longintactandinminent Jun. 23 at 1:49 PM

$PSTV Marc just sign my BID and go to the Bahamas

0 · Reply

Longintactandinminent Jun. 23 at 1:48 PM

$PSTV ok ok Marc I forgive u for now

0 · Reply

Washingtonstate Jun. 23 at 1:45 PM

$PSTV

1 · Reply

plustherapeutics Jun. 23 at 1:26 PM

$PSTV announces that management will host a business update conference call and webcast on Tuesday, June 30, 2026, at 8:30 a.m. Eastern Time. Full press release here: https://ir.plustherapeutics.com/news-releases/news-release-details/plus-therapeutics-provide-business-update-call-june-30-2026

0 · Reply

jamesownsu Jun. 23 at 12:20 PM

$AMOD $CENN $CUPR $PSTV Cenn isng going to be low float much longer. Wang diluting tyd fuk out of this right now😂

0 · Reply

Bolleh Jun. 23 at 12:16 PM

$PSTV Business Update Call - might be some great updates, might be nothing at all. Gonna be interesting listening to it nontheless, but I don't expect anything other than just an update without any major news.

1 · Reply

focafoca99 Jun. 23 at 11:46 AM

$PSTV hosts a business update call on June 30 to discuss its CNSide diagnostic launch and Reyobiq development. https://www.rapidticker.com/news/pstv-plus-therapeutics-to-provide-business-a9158b

0 · Reply

Lehameri Jun. 23 at 10:59 AM

$PSTV sucks to see this retesting what i might be lows. Its been such a roller coaster. "We're going up." "Oh no, we're going down." "Wait, wait up?" "Oh, right."But it does make me happy for the sls crew that their patience is paying off. So it makes hopeful.

0 · Reply

Longintactandinminent Jun. 23 at 10:54 AM

$PSTV intact

0 · Reply

Marketmoverjoe Jun. 23 at 10:40 AM

$PSTV the daily 4% dilution. it's gonna be a great day, folks.

0 · Reply

1.0.0